Dr. Melnick on the Future of Chemotherapy in Lymphomas

Ari M. Melnick, MD
Published: Friday, Mar 22, 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses the future of chemotherapy in patients with lymphomas.

Melnick believes that chemotherapy is not required to cure lymphomas. Similar to other tumor types, lymphomas are dependent on several biological factors to survive and grow.

Lymphomas depend on lineage factors: proteins that are present without which the disease cannot survive. Further, somatic mutations occur in lymphomas and are targetable or represent targetable pathways. It is possible, Melnick says, to eradicate all lymphoma cells with targeted agents or various combinations of targeted agents. It is also becoming increasingly possible for agents to erase "instructions" (epigenetic settings) to destroy the disease.

Targeting pathways, lineage factors, and epigenetic settings provide physicians with three ways to combat lymphomas.

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses the future of chemotherapy in patients with lymphomas.

Melnick believes that chemotherapy is not required to cure lymphomas. Similar to other tumor types, lymphomas are dependent on several biological factors to survive and grow.

Lymphomas depend on lineage factors: proteins that are present without which the disease cannot survive. Further, somatic mutations occur in lymphomas and are targetable or represent targetable pathways. It is possible, Melnick says, to eradicate all lymphoma cells with targeted agents or various combinations of targeted agents. It is also becoming increasingly possible for agents to erase "instructions" (epigenetic settings) to destroy the disease.

Targeting pathways, lineage factors, and epigenetic settings provide physicians with three ways to combat lymphomas.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x